STOCK TITAN

Quoin Pharmaceuticals Ltd - QNRX STOCK NEWS

Welcome to our dedicated page for Quoin Pharmaceuticals news (Ticker: QNRX), a resource for investors and traders seeking the latest updates and insights on Quoin Pharmaceuticals stock.

Quoin Pharmaceuticals Ltd (QNRX) is a clinical-stage biopharmaceutical company pioneering therapies for rare dermatological disorders and orphan diseases. This dedicated news hub provides investors and healthcare professionals with timely updates on regulatory milestones, clinical trial progress, and strategic partnerships central to advancing treatments for conditions like Netherton Syndrome and Epidermolysis Bullosa.

Access authoritative information on Quoin's therapeutic pipeline developments, including FDA designations and international trial expansions. The page consolidates official press releases, research collaborations, and manufacturing updates while maintaining strict compliance with financial disclosure standards.

Key content areas include phase trial results, intellectual property announcements, and partnership agreements with biotechnology innovators. All materials are curated to support informed decision-making without speculative commentary or investment recommendations.

Bookmark this page for streamlined tracking of Quoin's progress in addressing unmet medical needs through targeted drug development programs and evidence-based research initiatives.

Rhea-AI Summary

Quoin Pharmaceuticals Ltd. has initiated its first clinical site for the QRX003 study, aimed at treating Netherton Syndrome, a rare genetic disorder. The randomized, double-blind, vehicle-controlled study will test two doses of QRX003 over a twelve-week period. With FDA discussions in progress, various clinical endpoints will be evaluated. The company aims to improve skin barrier function and patient quality of life. Quoin has already formed partnerships in 60 countries for potential market access post-approval, enhancing its global reach.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.08%
Tags
-
Rhea-AI Summary

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) received a notification from Nasdaq on June 10, 2022, indicating non-compliance with the minimum bid price requirement of $1.00 per share, necessitating corrective action within 180 days. This notification does not currently affect its Nasdaq listing. The company is also addressing earlier non-compliance regarding stockholders’ equity, having submitted a plan to Nasdaq for resolution. While the company remains operationally unaffected, the prospect of delisting poses a significant risk to shareholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.15%
Tags
none
-
Rhea-AI Summary

Quoin Pharmaceuticals has announced a significant agreement with Hong Kong WinHealth Pharma Group to license and distribute its lead product QRX003 for Netherton Syndrome in Greater China.

The agreement will expand access to rare disease treatments in Hong Kong, Macau, and Taiwan, contingent on regulatory approval, and brings Quoin's global partnerships for QRX003 to nearly 60 countries. With QRX003 potentially being the first treatment for this rare condition, clinical trials are expected to commence shortly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.53%
Tags
none
Rhea-AI Summary

Skinvisible, Inc. (OTCQB:SKVI) has announced that its licensee Quoin Pharmaceuticals (NASDAQ:QNRX) received FDA acceptance for an Investigational New Drug (IND) application for QRX003, a treatment for Netherton Syndrome. This marks the first IND approval using Skinvisible's proprietary Invisicare drug delivery technology. Successful clinical trials could lead to a milestone payment of $5 million and ongoing royalties for Skinvisible. The approval underscores the potential for expanding applications of their technology in treating rare skin disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.48%
Tags
none
-
Rhea-AI Summary

Quoin Pharmaceuticals has secured exclusive global rights to a product in development for scleroderma through a new agreement with Queensland University of Technology. This deal involves no upfront fees and allows Quoin to fund the pre-clinical program. The VCAM-1:VL-4 interaction targets immune response in scleroderma, a disease with no current cure. Additionally, Quoin received FDA clearance for its lead product, QRX003, targeting Netherton Syndrome, with clinical trials set to begin in Q2 2022. This positions Quoin to potentially deliver groundbreaking treatments for rare diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
none
-
Rhea-AI Summary

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has received FDA clearance to initiate clinical testing for its investigational product QRX003, aimed at treating Netherton Syndrome, a rare genetic condition with no current approved treatments. QRX003, a topical lotion that uses proprietary delivery technology, seeks to normalize skin shedding and improve skin barrier function. The company plans to begin clinical trials in the first half of 2022, marking a significant milestone for both Quoin and patients suffering from this serious condition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
none
Rhea-AI Summary

Quoin Pharmaceuticals has submitted an Investigational New Drug (IND) application to the FDA for its investigational product QRX003, targeting Netherton Syndrome, a rare genetic disorder with no current treatment options. QRX003 is a topical lotion formulated to restore the skin barrier in affected patients. This IND submission represents a significant milestone for the company as it aims to initiate clinical testing in Q2 2022. Quoin's pipeline also includes additional products for rare diseases, highlighting its commitment to addressing unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
none
-
Rhea-AI Summary

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has submitted a Scientific Advice Briefing Document to the European Medicines Agency (EMA) for QRX003, aimed at treating Netherton Syndrome, a rare genetic disease with no current cure. This submission is a critical first step towards advancing the treatment into clinical testing and potential commercialization in the EU. The company has integrated previous feedback received from the FDA into this submission, reflecting its commitment to addressing unmet medical needs in rare diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.38%
Tags
none
-
Rhea-AI Summary

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has expanded its partnership with ER-Kim to include six additional countries for the commercialization of QRX003, a treatment for Netherton Syndrome. This new agreement adds Turkey, Georgia, Azerbaijan, Greece, Cyprus, and Malta to the existing fifteen countries covered in the initial agreement. With this expansion, Quoin now has a total of 60 countries under distribution agreements for QRX003, which aims to be the first approved treatment for this rare genetic disorder lacking current therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.41%
Tags
none
Rhea-AI Summary

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has secured an exclusive agreement with Neopharm Medical Supplies to commercialize its investigational drug QRX003 in Israel. This marks the sixth distribution partnership for QRX003 since Quoin's NASDAQ debut in October 2021. The agreement aims to address Netherton Syndrome, a rare genetic disorder with no existing treatment. Quoin's CEO, Dr. Michael Myers, emphasized the importance of expanding the distribution network to ensure global access for patients once the product is approved.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.9%
Tags
none
Quoin Pharmaceuticals Ltd

Nasdaq:QNRX

QNRX Rankings

QNRX Stock Data

3.22M
546.53k
6.59%
7.51%
32.72%
Biotechnology
Pharmaceutical Preparations
Link
United States
KFAR SABA